series-c-plus
Stage
3
Investors
About
Progentos is developing novel small-molecule therapeutics that activate oligodendrocyte progenitor cells to regenerate myelin and repair neurological damage caused by multiple sclerosis.
Explore Progentos's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.